5 Hrs
المصدر:
Forbes
Gilgamesh Challenges Big Pharma's Psychedelic Reach
A biotech startup sold a psychedelic compound to AbbVie for $1.2 billion last year. Its founders are now developing additional compounds aimed at treating depression and other mental health conditions.
articleDetails.fontSize.sizeحجم النص
تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي
comments.heading